knowledge -WSS

knowledge

author：knowledge 2025-10-01 11:43:50 - browse：7731

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA sets aggressive timeline for overhauling inspection procedures

hotspot

WSS

Physician groups backed by private equity giant lobby on mergers

Scientists inch closer to single

Sage hopes for a blockbuster in antidepressant now before FDA

Mega Millions pot grows to $1.25 billion after no winner

Microsoft launches AI tool for clinical documentation through Epic

Maisha Meds is a PBM, but don't call it that

knowledge

knowledge

explore

At least 13 dead in Texas as scorching temps continue

Physician groups backed by private equity giant lobby on mergers

Medicare proposal to cover medical devices draws a mixed reaction

5 important ways Henrietta Lacks changed medical science

Supreme Court strikes down use of affirmative action

5 important ways Henrietta Lacks changed medical science

Medical leaders decry Supreme Court decision on affirmative action

Medicare bonuses could stop drug shortages under Senate plan

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New safety details link Apellis eye drug to rare cases of blindness

entertainment

EQRx, failed developer of low

New safety details link Apellis eye drug to rare cases of blindness

What the US credit downgrade means for the economy, your finances

The high personal cost of affirmative action for Black doctors

The inclusion problem at the heart of rehabilitation research

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

hotspot

hotspot

leisure time

leisure time